This HTML5 document contains 51 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n18http://localhost/temp/predkladatel/
n16http://linked.opendata.cz/resource/domain/vavai/projekt/
n7http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n14http://linked.opendata.cz/resource/domain/vavai/subjekt/
n13http://linked.opendata.cz/ontology/domain/vavai/
n10http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n8http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61989592%3A15310%2F12%3A33117762%21RIV13-MSM-15310___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n20http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n17http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61989592%3A15310%2F12%3A33117762%21RIV13-MSM-15310___
rdf:type
n13:Vysledek skos:Concept
dcterms:description
Association of trough imatinib plasma levels (IPL) with cytogenetic or molecular response to treatment in patients with chronic myeloid leukemia (CML) was repeatedly reported. We analyzed their value in the routine clinical setting in 131 patients with chronic phase CML in whom imatinib was applied as first- or second-line treatment. A total of 1,118 measurements were obtained by ultra-performance liquid chromatography-tandem mass spectrometry assay in patients treated with daily dose of imatinib ranging from 100 to 800 mg. Samples were obtained from 1 to 96 h after drug ingestion. High inter (36%) and intraindividual variability (9-33%) of IPL was observed. For analysis of correlation of IPL with treatment response, two sets of samples were selected according to the European LeukemiaNet (ELN) criteria. The first set consisted of 241 samples taken 24 +- 2 h after dosing in 54 patients, and the second one consisted of 329 samples taken 24 +- 4 h after imatinib ingestion in 84 patients. In both sets, only patients treated with 400 mg imatinib once daily for at least 18 months were included. From multiple measurements in individual patients, mean IPL were used. In both sets, we were not able to demonstrate a statistically significant correlation between IPL and response to treatment according to the ELN. We believe that this was due to the differences in patients' compliance, leukemia biology, and other variables that are difficult to eliminate in the routine clinical practice. The use of IPL for prognostic estimation in CML treatment outside the clinical trials is probably limited. Association of trough imatinib plasma levels (IPL) with cytogenetic or molecular response to treatment in patients with chronic myeloid leukemia (CML) was repeatedly reported. We analyzed their value in the routine clinical setting in 131 patients with chronic phase CML in whom imatinib was applied as first- or second-line treatment. A total of 1,118 measurements were obtained by ultra-performance liquid chromatography-tandem mass spectrometry assay in patients treated with daily dose of imatinib ranging from 100 to 800 mg. Samples were obtained from 1 to 96 h after drug ingestion. High inter (36%) and intraindividual variability (9-33%) of IPL was observed. For analysis of correlation of IPL with treatment response, two sets of samples were selected according to the European LeukemiaNet (ELN) criteria. The first set consisted of 241 samples taken 24 +- 2 h after dosing in 54 patients, and the second one consisted of 329 samples taken 24 +- 4 h after imatinib ingestion in 84 patients. In both sets, only patients treated with 400 mg imatinib once daily for at least 18 months were included. From multiple measurements in individual patients, mean IPL were used. In both sets, we were not able to demonstrate a statistically significant correlation between IPL and response to treatment according to the ELN. We believe that this was due to the differences in patients' compliance, leukemia biology, and other variables that are difficult to eliminate in the routine clinical practice. The use of IPL for prognostic estimation in CML treatment outside the clinical trials is probably limited.
dcterms:title
Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting
skos:prefLabel
Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting
skos:notation
RIV/61989592:15310/12:33117762!RIV13-MSM-15310___
n13:predkladatel
n14:orjk%3A15310
n3:aktivita
n4:Z n4:S n4:P
n3:aktivity
P(ED0030/01/01), P(NT12218), S, Z(MSM6198959205), Z(MSM6198959223)
n3:cisloPeriodika
6
n3:dodaniDat
n17:2013
n3:domaciTvurceVysledku
n7:6401309
n3:druhVysledku
n11:J
n3:duvernostUdaju
n20:S
n3:entitaPredkladatele
n8:predkladatel
n3:idSjednocenehoVysledku
140527
n3:idVysledku
RIV/61989592:15310/12:33117762
n3:jazykVysledku
n12:eng
n3:klicovaSlova
treatment response; plasma levels; Imatinib; chronic myeloid leukemia
n3:klicoveSlovo
n5:plasma%20levels n5:Imatinib n5:treatment%20response n5:chronic%20myeloid%20leukemia
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[574CFA8ACDBD]
n3:nazevZdroje
Annals of Hematology
n3:obor
n9:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
8
n3:projekt
n16:NT12218 n16:ED0030%2F01%2F01
n3:rokUplatneniVysledku
n17:2012
n3:svazekPeriodika
91
n3:tvurceVysledku
Faber, Edgar Jarošová, Marie Rožmanová, Šárka Indrák, Karel Mičová, Kateřina Divoká, Martina Friedecký, David Adam, Tomáš
n3:zamer
n10:MSM6198959223 n10:MSM6198959205
s:issn
0939-5555
s:numberOfPages
7
n18:organizacniJednotka
15310